Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)

International Journal of Cancer

Volumn 121, Issue 12, 2007, Pages 2794-2800

  Kaufmann, Andreas M ^a,o   Nieland, John D ^b   Jochmus, Ingrid ^b,p   Baur, Siegfried ^c   Friese, Klaus ^c,d,e   Gabelsberger, Joseph ^b   Gieseking, Friederike ^f   Gissmann, Lutz ^g   Glasschröder, Birgit ^b   Grubert, Thomas ^c   Hillemanns, Peter ^h   Höpfl, Reinhard ⁱ   Ikenberg, Hans ^j   Schwarz, Jörg ^f   Karrasch, Matthias ^b   Knoll, Anette ^b   Küppers, Volkmar ^k   Lechmann, Martin ^b   Lelle, Ralph J ^l   Meissner, Harald ^b   Müller, Rainer T ^b   Pawlita, Michael ^g   Petry, Karl Ulrich ^m   Pilch, Henryk ⁿ   Walek, Elke ^b   Schneider, Achim ^a,o   more..

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b MediGene AG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j CytoMol   (Germany)

^k HEINRICH HEINE UNIVERSITY   (Germany)

^l UNIVERSITY OF MÜNSTER   (Germany)

^m Klinikum der Stadt Wolfsburg   (Germany)

ⁿ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^p NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Antibody; Cervical cancer; Clinical trial; Immunization; T cell

Indexed keywords

ONCOLYTIC HUMAN PAPILLOMAVIRUS TYPE 16 LE17; ONCOLYTIC VIRUS; PLACEBO; UNCLASSIFIED DRUG;

ARTHRITIS; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; LIVER FUNCTION; METRORRHAGIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE; VACCINATION;

EID: 36248945563     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23022     Document Type: Article

References (35)

1. Shah KV, Howley PM. Papillomaviruses. In: Fields BN, ed. Virology, 2nd edn. New York: Raven Press, 1990. 1651-78.
2. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
3. IARC. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC, 1995
4. Suris JC, Dexeus S, Lopez-Marin L. Epidemiology of preinvasive lesions. Eur J Gynaecol Oncol 1999;20:302-5
5. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R; IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-8.
6. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
7. Van Beurden M. VIN III - Aspects of etiology, diagnostics and treatment. Amsterdam: Amsterdam, 1998.
8. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67:665-9.
9. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808-16.
10. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92.
11. Cirisano FD. Management of pre-invasive disease of the cervix. Semin Surg Oncol 1999;16:222-7.
12. Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000;79:294-9.
13. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, et al.; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
14. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR. Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE. Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;5:271-8.
15. Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L. Chimeric papillomavirus-like particles. Virology 1997;234:93-111.
16. Munger K, Scheffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992;12:197-217.
17. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999;81:881-8.
18. Ohlschlager P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Muller M, Pawlita M, Schafer K, Sehr P, Staib C, Sutter G, et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003;77:4635-45.
19. Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Muller RT, Jochmus I, Gissmann L, Schneider A, Durst M. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001;92:285-93.
20. Freyschmidt EJ, Alonso A, Hartmann G, Gissmann L. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther 2004;9:479-89.
21. Jacobs MV, Snijders PJ, van den Brule AJ, Heimerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-5.
22. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005;51:1845-53.
23. Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001;253:153-62.
24. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
25. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003;95:1128-37.
26. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 2001;290:350-60.
27. Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003;21:3219-27.
28. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998;95:1800-5.
29. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 1999;30:269-74.
30. Neubert RT, Webb JR, Neubert D. Feasibility of human trials to assess developmental immunotoxicity, and some comparison with data on New World monkeys. Hum Exp Toxicol 2002;21:543-67.
31. Perez-Diez A, Spiess PJ, Restifo NP, Matzinger P, Marincola FM. Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 2002;168:338-47.
32. Nieland JD, Loviscek K, Kono K, Albain KS, McCall AR, Potkul RK, Fisher SG, Velders MP, Petersson M, Kiessling R, Kast WM. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. J Immunother 1998;21:317-22.
33. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999;48:353-62.
34. de Visser KE, Kast WM. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 1999;13:1188-99.
35. Bubenik J. Tumour MHC class I downregulation and immunotherapy. Oncol Rep 2003;10:2005-8. (Review).